XTL Biopharma (XTLB) Posts Breakeven Q3 Loss
Get Alerts XTLB Hot Sheet
Join SI Premium – FREE
XTL Biopharma (NASDAQ: XTLB) reported Q3 EPS of ($0.00), versus ($0.00) reported last year.
XTL reported $2.3 million in cash and cash equivalents as of September 30, 2016. Funds will be used to advance the hCDR1 clinical program for the treatment of SLE, to investigate its use in other indications and to identify additional assets for the treatment of other autoimmune diseases.
For earnings history and earnings-related data on XTL Biopharma (XTLB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall
- Construction Partners, Inc. (ROAD) Tops Q2 EPS by 2c ; Offers Guidance
- eFFECTOR Therapeutics, Inc. (EFTR) Tops Q1 EPS by 84c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!